

A silhouette of a person standing on a cliff overlooking the ocean at sunset. The sun is low on the horizon, creating a bright glow and casting long shadows. The sky is filled with scattered clouds, and the ocean is visible in the distance.

# Harnessing Nano for Drug Delivery

Kayte Fischer

3/17/15

# What is Drug Delivery?



VIDEO · POLITICS · SPORTS · SCIENCE/TECH · LOCAL · ENTERTAINMENT

## Pfizer Kingpin Gunned Down In Ongoing Prescription Drug Cartel Turf War

NEWS · Crime · Drugs · News · ISSUE 49-11 · Mar 15, 2013

 Share on Facebook

5.9K

 Share on Twitter

537




110




# What is Drug Delivery?



# Why is drug delivery useful?




# Opportunities Incorporating Existing Drugs




\*Data for comparable products presented by Teva Pharmaceuticals at PODD conference 2014

# Different Systems, Different Hurdles



- Mucosal (Oral, gastrointestinal, buccal, ocular, vaginal, alveolar, bronchial)
  - Thick coating of slow-flowing mucus
  - Often active immune response
- Dermal
  - Thick and hydrophobic
  - Exposed externally
- Parenteral (Intravenous, intramuscular, subcutaneous, cranial)
  - Needles/invasive
- General
  - Bioavailability (eg: hepatic first pass clearance)


# What's going on in the body at the nano level?



- Transportation
  - Internalization (eg: vesicles)
  - Migration (eg: cilia)
  - Reorganization (eg: microvilli)
- Actuation
  - DNA replication
- Communication
  - Receptor binding

# Why Micro/Nano?

- Unique properties
  - Surface area to volume ratio
  - Integration with electronics
  - Scalable manufacturing via semiconductor techniques
  - Novel material properties (color, electrical properties, etc)
- Biological scale
  - Cell membrane interactions
  - Cell signaling interactions
  - Close in size to macromolecules






# Opportunities for Nano-Enabled Drug Delivery


## Free floating

- Nanoparticles






## Coatings/integral

- Nanowires
- Nanopores/Nanotubes




Popat, et al. *Biomaterials* 28 (2007).

# Cell-Nanowire Interface



Nanowires and microvilli  
are similar in scale


# Cell-Nanowire Interface





Nanoscale features allow interdigitation with microvilli, leading to increased van der Waals force

Fischer, Kathleen (2010) Doctoral Dissertation. Silicon Nanowires for Bioadhesion and Drug Delivery.

# Nanocoatings






<https://pharm.ucsf.edu/desai/research/vascular-stents>




Kam, et al. Nano Letters, 2013.


# Diffusion from Nanoporous Silicon Membranes



Experimental Details			
Molecule	nCH (nm)	Solution Conc. (mg/mL)	Release Rate (µg/day)
DF-1 Fullerene	5	2	20
DF-1 Fullerene	13	2	exp.
Glucose	5	495.44	exp.
FITC-Dextran	22	5	17
BSA	22	20	30
BSA	22	40	30
INFα-2b	13	1	6





Martin et al., 2005, Journal of Controlled Release




Lopez et al., 2006, Biomaterials

Fine et al., Lab on a Chip, 2010



# Inorganic Nanoporous Devices



Titania  
nanotubular  
membranes




Scale bar –  
500 nm




Alumina nanoporous  
capsules

Silicon  
nanochannels



Drug  
Reservoir



NanoPortal<sup>TM</sup>  
Membrane



**Nano Precision Medical**

*[www.nanoprecisionmedical.com](http://www.nanoprecisionmedical.com)*

# Management Team

## Original Founding Team



Adam Mendelsohn, PhD  
Chief Executive Officer  
Director




Kayte Fischer, PhD  
Chief Technology Officer



Lily Peng, MD, PhD  
Consulting VP of Clinical  
Development

## Non-Founding Management



Tomoyuki Yoshie, PhD  
VP of Device Research






Wouter Roorda, PhD  
VP of Pharmaceutical  
Product Development




Adam Monkowski, PhD  
VP of Device Technology  
Development




# Benefits of NanoPortal Device




# NanoPortal™ Membrane




# As-Fabricated Titania Nanotubes



Tube bottoms, as fabricated  
Diameters can be modified




Side view  
~60 microns  
Most lengths can  
be achieved




Nanotube tops  
Diameters can be modified

# Nanoscale Constrained Release


NanoPortal™  
Technology



**Fickian**, diminishing  
release-rate over time




**Non-Fickian**, constant  
release-rate over time





Drug release curves over time

# NanoPortal™ Exhibits Size-Dependent Constant-Rate Delivery


(data produced from prior-generation membranes)



Polyethylene glycol, 40 kDa,  
Fickian release




FITC-Fab<sub>2</sub>, 110 kDa,  
Constant-rate release




*Similar membranes used for both molecules*


# Controllable Nanotube Diameters



0 nm pore size




17 nm pore size



33 nm pore size


← Decreasing nanotube diameter

# Devices Function in Rats



Identical devices tested in parallel *in vitro* (top) and *in vivo* (bottom);  
n=5  
Decays as expected after delivery is complete

# NanoPortal™ as a Platform Technology





# Classes of Ideal Drug Candidates

- Selection Criteria
1. Chronic treatments
  2. Constant-rate delivery is desirable

Molecule Type	Example	Indication
Small Molecules with Compliance Issues	Anti-psychotics (Risperidone)	Schizophrenia, Bipolar Disorder
Small Peptides / Hormones	GLP-1 Agonist (Exenatide)	Diabetes
Enzyme Replacements	Glucocerebrosidase (Cerezyme)	Gaucher, Fabry
Antibodies	Natalizumab (Tysabri)	Multiple Sclerosis
siRNA	Miravirsen	HCV

**Top Pipeline Opportunities:**  
Exenatide,  
Teduglutide,  
Octreotide

# The Original Idea and Team

Meeting w/ Adam (+Tejal) 11/1/07  
Re: BNOC

**TO DO:** Nov/Monday  
 date initial -  
 needs/why  
 - on a level for their  
 - scale w/ of being  
 Lysozymal  
 membrane  
 boiling of TI  
 (crust-formability)  
 cost analysis  
 P stuff? - POSS  
WCSF

Due: 11/7/07 - ABSTRACT

Ti NT → Hep C, Intest →  
(w/ oral riboflavin)

Recesses → support (Leimes is working on)  
 - Refill device from outside (1-3 mos)  
 - peritoneal cavity implant → use w/ oral riboflavin

competitive landscape? DEVICE PERSPECTIVE  
 → how diff from polymer?  
 ALTS: Pumps, Medtronic??

dictates release characteristics/care  
 dictates quantity

What type of I? same formulation  
 need @ least 3 mos to be better  
 than / day injections  
 \* one mo is ok, if refill, but only  
 replace > 3 mos (eg: 6 mos)  
 for Hep C

fallbacks, ?'s: Is it worth it for market size?  
 cost, Scalability - no need clean room, need HF

good for drugs w/ patient compliance  
 refractance

animal trials - study ~~work~~ salaries  
 (\$20 for Buekingame place) for proof of concept

FDA - not quick - device + drug combop; 3-5 yrs

**TEAM I**

3/30/0 SCIENCE

BUSINESS ADVISORS

LEGAL IP ATTORNEY HIRSH PARRIS

LIU

ADAM

KAYTE

lab

WILL

EVAN FAMILY BACKUP

CH OUT CH OUT

# Getting Started (2007-2010)


- Business plan competitions – 2007-2009
- Grant funding – 2009
- Incorporation – 2009

3 Co-founders

- IP negotiations – 2010

2 Co-founders + 1 Employee





# Initial Incubator (2010-2011)



- Moved into incubator lab at UC Berkeley


2 Co-founders + 1 Employee



# The East Bay Innovation Center (2011-2013)


- 2 offices!
- 5 lab benches!
- Lots of shared facilities, for better or worse

2 Co-founders +  
1 -> 5 Employees = 7





# Facility Upgrade! (2013-present)

2 Co-founders +  
5 -> 10 Employees + 1-2 Interns = 13-14!



< 500 sq ft  
to > 6000 sq  
ft



slightly larger than a grain of rice

LEARN MORE ABOUT NANOPORTAL™ TECHNOLOGY >



**Thank you for your attention!**

Contact: Kayte Fischer  
kayte@nanoprecisionmedical.com  
www.nanoprecisionmedical.com